Overexpression of miR-196b and HOXA10 characterize a poor-prognosis gastric cancer subtype

Table 1 Clinicopathologic factors of patients with gastric cancer participating in the microarray analysis n (%)

Characteristic	Group 1 (n = 60)	miR-196b high (n = 28)	miR-196b low (n = 29)	P value	HOXA10 high (n = 29)	HOXA10 low (n = 28)	P value
Age, yr
Median (range)	63 (32-83)	66 (34-78)	58 (32-83)	0.134	64 (34-83)	60 (32-78)	0.134
> 65		15 (52)	9 (32)		15 (52)	9 (32)
Sex
Male	41 (68)	19 (68)	20 (69)	0.928	18 (62)	21 (75)	0.294
Histologic type
Diffuse	27 (45)	9	17	0.066	8	18	0.007
Intestinal	23 (38)	14	9		16	7
Mixed	10 (17)	5	3		5	3
T stage
T1/T2	26 (43)	10 (36)	14 (48)	0.337	11 (38)	13 (46)	0.516
T3/T4	34 (57)	18 (64)	15 (52)		18 (62)	15 (54)
N stage
N0/N1	36 (60)	15 (54)	19 (66)	0.358	16 (55)	18 (64)	0.483
N2/N3	24 (40)	13 (46)	10 (34)		13 (45)	10 (36)
AJCC stage1
I/II	23 (38)	11 (39)	12 (41)	0.872	11 (38)	12 (43)	0.705
III/IV	37 (62)	17 (61)	17 (59)		18 (62)	16 (57)

¹Based on the American Joint Committee on Cancer staging manual 6^th edition. HOXA10: Homeobox A10; AJCC: American Joint Committee on Cancer.

Table 2 microRNAs differentially expressed in gastric cancer tissues; non-cancer tissue and C1 and C2 groups (P < 0.05)

Name	Chromosome location	Function	Related gene	Related cancer	References
Expression level: C1 > C2 > non-cancer
hsa-miR-196b	7p15.2	Tumor suppressor, progression	HOXA, HOXC8	T-cell ALL, MLL-rearranged leukemia, ALL, stomach, lung, pancreas	18,19,27,28
hsa-miR-135b	1q32.1	Tumorigenesis	FOXO1, APC	Leukemia, anaplastic large cell lymphoma, pancreas, colon, prostate, osteosarcoma	29-31
hsa-miR-93	7q22.1	Tumorigenesis, progression, prognosis	E2F1, ZBTB4, FUS1, TP53INP1, ITGB8, VEGFA, CDKN1A	Kidney, breast, colon, liver, stomach, lung, osteosarcoma, adult T-cell leukemia	17,32-37
Expression level: C1 < C2 < non-cancer
hsa-miR-29c*	1q32.2	Prognosis		Malignant pleural mesothelioma	38

ALL: Acute lymphoblastic leukemia; MLL: Mixed lineage leukemia gene; HOXA10: Homeobox A10.